First Time Loading...

Sonoma Pharmaceuticals Inc
NASDAQ:SNOA

Watchlist Manager
Sonoma Pharmaceuticals Inc Logo
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Watchlist
Price: 0.1663 USD 0.73%
Updated: Mar 29, 2024

Intrinsic Value

SNOA doesn't have a meaningful market cap.
SNOA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasa... [ Read More ]

The intrinsic value of one SNOA stock under the Base Case scenario is 3.622 USD. Compared to the current market price of 0.1663 USD, Sonoma Pharmaceuticals Inc is Undervalued by 95%.

Key Points:
SNOA Intrinsic Value
Base Case
3.622 USD
Undervaluation 95%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Financials

Balance Sheet Decomposition
Sonoma Pharmaceuticals Inc

Current Assets 12.5m
Cash & Short-Term Investments 2.4m
Receivables 2.9m
Other Current Assets 7.2m
Non-Current Assets 2.1m
PP&E 738k
Other Non-Current Assets 1.4m
Current Liabilities 3.1m
Accounts Payable 864k
Accrued Liabilities 2m
Short-Term Debt 44k
Other Current Liabilities 138k
Non-Current Liabilities 4.9m
Other Non-Current Liabilities 4.9m
Efficiency

Earnings Waterfall
Sonoma Pharmaceuticals Inc

Revenue
12.3m USD
Cost of Revenue
-7.5m USD
Gross Profit
4.8m USD
Operating Expenses
-9m USD
Operating Income
-4.1m USD
Other Expenses
-934k USD
Net Income
-5.1m USD

Free Cash Flow Analysis
Sonoma Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SNOA Profitability Score
Profitability Due Diligence

Sonoma Pharmaceuticals Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROIC
17/100
Profitability
Score

Sonoma Pharmaceuticals Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

SNOA Solvency Score
Solvency Due Diligence

Sonoma Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
50/100
Solvency
Score

Sonoma Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SNOA Price Targets Summary
Sonoma Pharmaceuticals Inc

There are no price targets for SNOA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SNOA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SNOA Price
Sonoma Pharmaceuticals Inc

1M 1M
+13%
6M 6M
-78%
1Y 1Y
-82%
3Y 3Y
-98%
5Y 5Y
-98%
10Y 10Y
-100%
Annual Price Range
0.1663
52w Low
0.134
52w High
1.4
Price Metrics
Average Annual Return -23.28%
Standard Deviation of Annual Returns 58.4%
Max Drawdown -99%
Shares Statistics
Market Capitalization 2.6m USD
Shares Outstanding 15 607 400
Percentage of Shares Shorted 0.79%

SNOA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Sonoma Pharmaceuticals Inc Logo
Sonoma Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

2.6m USD

Dividend Yield

0%

Description

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.

Contact

GEORGIA
Woodstock
645 Molly Lane, Suite 150
+18007599305.0
https://sonomapharma.com/

IPO

2007-01-26

Employees

13

Officers

CEO, President & Director
Ms. Amy M. Trombly
Interim Chief Financial Officer
Mr. Jerome J. Dvonch
COO & Corporate Secretary
Mr. Bruce Thornton
Controller
Mr. John Dal Poggetto

See Also

Discover More